萌妹社区

July 24, 2015

AbbVie beats 2Q profit forecasts, but sales fall short

This Jan. 24, 2015, file photo, shows the exterior of Abbvie, in Lake Bluff, Ill. AbbVie Inc. reports quarterly financial results on Friday, July 24, 2015. (AP Photo/Nam Y. Huh)
× close
This Jan. 24, 2015, file photo, shows the exterior of Abbvie, in Lake Bluff, Ill. AbbVie Inc. reports quarterly financial results on Friday, July 24, 2015. (AP Photo/Nam Y. Huh)

Drugmaker AbbVie Inc. reported better-than-expected second-quarter profit, but its sales disappointed Wall Street.

The North Chicago, Illinois-based company, which makes the blockbuster anti-inflammatory drug Humira, saw profit rise 24.4 percent to $1.37 billion, or 83 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, came to $1.08 per share.

The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.06 per share.

Revenue rose 11.1 percent to $5.48 billion, mainly on a boost in sales of Humira. But, the results fell shy of Wall Street expectations, with five analysts surveyed by Zacks expecting $5.6 billion.

Humira sales rose 7.6 percent to $3.54 billion. The company relies on the drug for the majority of its revenue. It is approved to treat more than a dozen conditions including rheumatoid arthritis, psoriasis and Crohn's Disease. But, it will start losing patent protection next year and could eventually face competition from Amgen Inc., which is developing a biosimilar version of the drug.

AbbVie's second-biggest seller, the hepatitis C drug Viekira Pak, was approved in December and brought in $385 million during the second quarter.

Viekira faces a crowded market with already established hepatitis C treatments including Gilead Sciences' Sovaldi and Harvoni. All three treatments are considered major improvements from earlier drug options.

Looking ahead, AbbVie expects full-year earnings in the range of $4.10 to $4.30 per share.

AbbVie's stock shed $2.02, or 2.9 percent, hitting $68.50 in premarket trading.

AbbVie shares have risen almost 8 percent since the beginning of the year, while the Standard & Poor's 500 index has increased 2 percent. The stock has increased 29 percent in the last 12 months.

_____

Elements of this story were generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on ABBV at

_____

Keywords: AbbVie, Earnings Report

Load comments (0)

This article has been reviewed according to Science X's and . have highlighted the following attributes while ensuring the content's credibility:

Get Instant Summarized Text (GIST)

This summary was automatically generated using LLM.